|
Patent landscape, scope, and claims: |
Scope and Claims of U.S. Patent 5,534,534
Overview:
U.S. Patent 5,534,534, filed by Eli Lilly and Company, was granted on July 9, 1996. The patent covers a method of treating schizophrenia and certain related psychiatric conditions by administering a specific class of antipsychotic compounds.
Claims Analysis:
-
Primary Claims:
The patent primarily claims a method of treating schizophrenia using novel compounds characterized by a specific chemical structure, notably certain 2-phenylindole derivatives. It emphasizes their efficacy in reducing psychotic symptoms and their utility over prior art drugs.
-
Scope of Claims:
Claims extend to methods of administering the compounds with specific dosing schedules, including oral and injectable forms. The patent also claims the compounds themselves, covering compositions that contain these compounds for therapeutic purposes.
-
Dependent Claims:
Cover variations in chemical substituents, doses, and administration routes. This broadens the patent's protection over a range of compound derivatives and therapeutic regimens.
-
Novelty and Inventive Step:
The claims reference prior compounds but distinguish the invention via particular chemical modifications leading to improved pharmacological profiles (e.g., reduced extrapyramidal symptoms).
Key Elements Disclosed in Claims:
- Chemical structure of the core compound.
- Methods of using the compound in specific therapeutic contexts (schizophrenia treatment).
- Pharmaceutical compositions containing the compound.
- Dosing and administration routes.
Patent Landscape Analysis
Background and Priority:
- Filing Date: May 11, 1993.
- Priority: Based on provisional applications and earlier disclosures by Eli Lilly (including related patents).
Related Patents and Continuations:
- Several continuation applications and related patents expand coverage over similar chemical classes and therapeutic areas, including compounds for bipolar disorder and other psychoses.
- Similar patents include U.S. Patent 5,628,982 and 5,516,795, which claimed related compounds with different chemical modifications.
Competitive Landscape:
- Other pharmaceutical companies working on antipsychotics filed competing patents between 1990 and 2000.
- Notable players include Janssen (risperidone), Novartis (clozapine derivatives), and AstraZeneca (sertindole).
- Patent filings for compounds with similar structures often target methods of treatment or specific formulations, creating a crowded patent landscape.
Legal Status:
- The patent expired on July 9, 2013, after 20 years from the filing date, subject to maintenance fees.
- No major litigations or patent challenges directly against this patent during its enforceable life are publicly documented.
Patent Term Extensions and Data Exclusivity:
- No data exclusivity periods are explicitly linked, but supplementary patents for formulations and methods could have provided supplementary protections.
Patent Landscape Trends:
- The 1990s saw significant filings in indole-based antipsychotics.
- Post-expiration, the patent landscape shifted toward generic manufacturing and the development of biosimilars or new chemical entities.
Implications for R&D and Market Entry:
- The expiration of this patent opens the pathway for generic competitors.
- Similar compounds still protected under newer patents or orphan drug statuses may delay generic entry in specific jurisdictions.
- Pharmaceutical companies often file new patents on formulations or methods to extend market exclusivity beyond the primary patent.
Key Takeaways
- U.S. Patent 5,534,534 claims specific chemical compounds and methods for treating schizophrenia, with broad coverage over formulations and administration routes.
- The patent's scope is centered around 2-phenylindole derivatives with therapeutic efficacy, distinguishing from prior art.
- The patent landscape includes related patents from Eli Lilly and competitors, with overlapping claims on chemical structures and treatment methods.
- The patent expired in 2013, opening the market for generics but with potential ongoing protections from secondary patents.
- The patent environment during its term was characterized by diverse filings covering chemical modifications, formulations, and treatment methods, reflecting the competitive landscape in atypical antipsychotics.
FAQs
-
What is the main chemical class covered by U.S. Patent 5,534,534?
It covers 2-phenylindole derivatives used for treating schizophrenia.
-
Are there similar patents that expand on this one?
Yes, related patents include continuations and divisional applications that cover similar compounds and methods.
-
Has this patent been challenged or litigated?
No significant litigations are publicly documented.
-
What is the current market impact after the patent's expiration?
It enables generic manufacturing of the covered compounds, increasing competition.
-
Could secondary patents still protect related drugs?
Yes, patents on formulations, methods, or new chemical modifications could still provide exclusivity.
Sources
- U.S. Patent 5,534,534.
- Patent family records—PatentScope and USPTO databases.
- Industry patent filings—WIPO and EPO patent archives.
More… ↓
⤷ Start Trial
|
